Showing 1 - 20 of 24 results
Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.
Tool developed for producing F-18 radiopharmaceuticals for PET imaging.
Twenty-four participants from Asia and the Pacific travelled to ANSTO for an International Atomic Energy Agency Regional Training Course on ‘Production and preclinical evaluation of emerging cyclotron-based radiopharmaceuticals’
An ANSTO radiochemist has been awarded a scholarship to carry out research at the world-renowned Sloan Kettering Cancer Center in New York.
ANSTO is a major supplier of Australia’s radioactive isotopes used in nuclear medicine, delivering around 10,000 patient doses each week. Health-based research and development in Australia and overseas also benefit greatly from ANSTO’s unique capabilities and expertise in the detection, diagnosis and treatment of disease using nuclear and accelerator infrastructure.
ANSTO today welcomed a significant Federal Government funding allocation to further safeguard the production of life-saving nuclear medicines in Australia.
Excellent radiolabelling facilities and the operation of OPAL, a world-class multi-purpose nuclear reactor, enable ANSTO to produce a large range of radioisotopes for Australian researchers in both radiopharmaceutical and environmental areas.
ANSTO provides access to specialised facilities and capabilities by application. Please ensure that you contact the relevant ANSTO scientist for advice before submitting a proposal.
ANSTO is a unique national science organisation that began operating under its predecessor The Australian Atomic Energy Commission (AAEC) 70 years ago.
ANSTO maintains national capabilities in radionuclide metrology, the measurement and detection of ionising radiation, radioanalytical chemistry and nuclear forensics to support industry, government and scientific users.
Research and development activity explores new, boutique radioisotopes, including positron, gamma and beta/gamma emitter. The aim is to provide material for the next generation of diagnostic and therapeutic radiopharmaceuticals
In January 2026, Mr Michael Quigley AM, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry and Innovation, and Minister for Science.
ANSTO has safely managed its radioactive waste for over 60 years. Waste is managed in accordance with national and international standards.